-5%
Vivicit contains Citicoline, a naturally occurring substance vital for the production of phospholipids in cell membranes. When taken orally, Citicoline is metabolized into choline and cytidine, both of which cross the blood-brain barrier and recombine to form Citicoline within the brain. This process activates the production of phospholipids in neuronal membranes, helping to repair damaged cells and mitochondrial membranes quickly.
Citicoline also increases neurotransmitter levels like acetylcholine and dopamine, which are crucial for brain function. Additionally, Citicoline provides neuroprotective effects during hypoxia (low oxygen levels) and ischemia (restricted blood flow), and supports cognitive functions such as learning and memory in aging brains.
Citicoline’s mechanism also includes inhibiting Phospholipase A2, a key enzyme involved in apoptotic (programmed) and necrotic (cell death due to injury) processes, thus contributing to cell survival and repair.
Vivicit is primarily indicated for the treatment of various neurological conditions, including:
- Cerebrovascular Diseases: Particularly effective for ischemia resulting from stroke, Vivicit accelerates recovery of consciousness and helps overcome motor deficits. Administering Vivicit within the first 24 hours of a stroke can significantly increase the chances of complete recovery after 3 months, particularly in patients with moderate to severe stroke.
- Cerebral Insufficiency: This includes symptoms like dizziness, memory loss, poor concentration, and disorientation caused by head trauma or brain injury.
- Cognitive Dysfunction in Degenerative Diseases: Vivicit is beneficial in improving cognitive function in conditions such as Alzheimer’s disease, where it supports memory and cognitive performance.
- Parkinson’s Disease: As a co-therapy, Vivicit has proven effective in managing Parkinson’s disease by improving motor function and cognitive abilities when used alongside other treatments.